Jonathan Chung to Antineoplastic Agents
This is a "connection" page, showing publications Jonathan Chung has written about Antineoplastic Agents.
Connection Strength
0.348
-
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019 06; 156(8):2242-2253.e4.
Score: 0.073
-
Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. Oncologist. 2019 06; 24(6):791-797.
Score: 0.072
-
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. Eur Urol. 2019 01; 75(1):201-203.
Score: 0.071
-
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. Eur Urol. 2018 07; 74(1):124-128.
Score: 0.070
-
Targeted mutations in the ATR pathway define agent-specific requirements for cancer cell growth and survival. Mol Cancer Ther. 2012 Jan; 11(1):98-107.
Score: 0.044
-
RET rearrangements are actionable alterations in breast cancer. Nat Commun. 2018 11 16; 9(1):4821.
Score: 0.018